Fundz

Precision BioSciences

Durham, North Carolina, United States · Biotechnology, Genetics, Health Care

Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Pre

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Headquarters
Durham, North Carolina, United States
Employees
106
Industries
Biotechnology, Genetics, Health Care
Status
Public (DTIL)
Website
precisionbiosciences.com
LinkedIn
Company page

Recent activity at Precision BioSciences

  • : SEC 8-K (8.01): On November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement for the issuance and sale of 10,235,077 shares of its common stock at a price of $7.75 per share, along with pre-funded warrants to purchase 5,893,964 shares at $7.749995 each. The expected net proceeds will enhance the company's liquidity and continue funding of its PBGENE-HBV and PBGENE-DMD clinical programs, ensuring sufficient capital into late 2029. The company anticipates that existing cash combined with the new offering will support critical next-stage developments in these programs.
  • : SEC 8-K (8.01): On November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement for an Offering of 10,235,077 shares of its common stock at $7.75 per share, alongside pre-funded warrants for 5,893,964 shares priced at $7.749995 each. The estimated net proceeds of approximately $116.5 million will be used for R&D on PBGENE-HBV and PBGENE-DMD and for general corporate purposes. The Offering's closing is set for November 6, 2026, pending customary conditions. The agreement includes significant terms for the pre-funded warrants, detailing their exercise and adjustment in case of corporate actions, and stipulates that holders won’t receive voting rights or other privileges typical of Common Stock holders.
  • : SEC 8-K (7.01): On August 24, 2026, Precision BioSciences, Inc. announced the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial, which is evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). This significant milestone took place at Arkansas Children’s Hospital, marking an important step in the clinical development of their gene therapy aimed at treating this genetic condition. The press release detailing this announcement is included as Exhibit 99.1 in the filing. This event highlights Precision BioSciences' ongoing commitment to advancing therapeutic options for patients with DMD, and is pivotal in the trajectory of their clinical program.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Employee benefit plans

Precision BioSciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

About Precision BioSciences: questions and answers

What does Precision BioSciences do?

Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Pre

Where is Precision BioSciences headquartered?

Precision BioSciences is headquartered in Durham, North Carolina, United States.

How many employees does Precision BioSciences have?

Precision BioSciences has about 106 employees.

What is the latest news on Precision BioSciences?

On Aug 24, 2026, SEC 8-K (8.01): On November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement for the issuance and sale of 10,235,077 shares of its common stock at a price of $7.75 per share, along with pre-funded warrants to purchase 5,893,964 shares at $7.749995 each. The expected net pr

Is Precision BioSciences a public company?

Yes. Precision BioSciences is publicly traded under the ticker DTIL.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Precision BioSciences across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.